Edoardo Peroni

Are all cases of paediatric essential thrombocythaemia really myeloproliferative neoplasms? Analysis of a large cohort.

Sporadic essential thrombocythaemia (ET) is rare in paediatrics, and the diagnostic and clinical approach to paediatric cases cannot be simply copied from experience with adults. Here, we assessed 89 children with a clinical diagnosis of ET and found that 23 patients (25·8%) had a clonal disease. The JAK2 V617F mutation was identified in 14 children, 1 child had the MPL W515L mutation, and 6 had CALR mutations. The monoclonal X‐chromosome inactivation pattern was seen in six patients (two with JAK2 V617F and two with CALR mutations). The other 66 patients (74·2%) had persistent thrombocytosis with no clonality. There were no clinical or haematological differences between the clonal and non‐clonal patients. The relative proportion of ET‐specific mutations in the clonal children was much the same as in adults. The higher prevalence of non‐clonal cases suggests that some patients may not have myeloproliferative neoplasms, with significant implications for their treatment.

Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia

Essential thrombocytemia (ET) may occur in women of childbearing age. Pregnancy may therefore be a common issue in the clinical management of young women with ET.[1][1],[2][2] Previous studies have shown live birth rates of 50% to 70% and spontaneous abortion rates of 25% to 50%, mostly during the

Discrepant ratios of arterial vs. venous thrombosis in hemophilias A and B as compared to FVII deficiency.

The occurrence of a thrombotic event in congenital bleeding disorders has drawn considerable attention in recent years. Both patients with hemophilia and patients with von Willebrand disease and even those with rare coagulation disorders have been shown to present occasional thrombotic events. Little is known on the comparative prevalence of arterial vs. venous thrombosis in these patients.

Venous thrombosis in von Willebrand disease as observed in one centre and as reported in the literature.

The aim of this article was to investigate the prevalence of venous thrombosis in patients with von Willebrand disease. Personal records on 486 patients were reevaluated together with a time unlimited PubMed search. The venous thrombotic event had to be proven by objective means. Only cases of congenital von Willebrand disease were taken into consideration and all types of the diseases were included. No case of venous thrombosis was reported in our cohort of patients. On the contrary, 33 patients with proven venous thrombosis were gathered from the literature (17 cases of deep venous thrombosis with or without pulmonary embolism; isolated pulmonary embolism was seen in seven instances, superficial veins or portal system thrombosis was present in the remaining cases). Associated risk factors, mainly replacement therapy, were present in 26 cases. Therapeutic approach was usually based on heparin and Coumadin. Overall results were fair or good, as no fatalities occurred.

The old and the new in prekallikrein deficiency: historical context and a family from Argentina with PK deficiency due to a new mutation (Arg541Gln) in exon 14 associated with a common polymorphysm (Asn124Ser) in exon 5.

Prekallikrein (PK) is one of the clotting factors involved in the contact phase of blood. PK has an important historical role as its deficiency state represents the second instance of a clotting defect without bleeding manifestations, the first one being factor XII deficiency. PK deficiency is a rare clotting disorder. Moreover, only 11 patients have been investigated so far by molecular biology techniques. In this article, we briefly review some of the history around PK and also present some recent data on a newly identified family from Argentina suffering from PK deficiency. Two patients are homozygous whereas other family members are heterozygous. PK activity and antigen are 1% of normal in the homozygotes and around 60 to 70% of normal in the heterozygotes. As expected, all patients are asymptomatic of bleeding or thrombosis presentations. However, the two homozygotes showed essential hypertension. The PK deficiency in this family is due to a new mutation (Arg541Gln) in exon 14. The defect segregates together with a known polymorphism, Asn124Ser, in exon 5. The significance of the presence of hypertension in the two homozygotes is discussed in view of the extra coagulation effects of PK on vasodilation, vessel permeability, and the control of blood pressure. Structure function analysis indicates that the substitution of Arg with Gln probably impedes the transmembrane diffusion of the molecule, which therefore cannot be secreted in the homozygotes. The presence of hypertension in patients with PK deficiency has been previously reported in some but not all patients. Future research activities will probably concentrate on the effect of PK and other contact phase factors on the vascular system.

Pulmonary embolism in congenital bleeding disorders: intriguing discrepancies among different clotting factors deficiencies.

Pulmonary embolism is a complication of deep vein thrombosis. It occurs in the population with a normal clotting mechanism, but it may also occur in patients with congenital bleeding conditions. Here, we report on all cases of pulmonary embolism in congenital hemorrhagic disorders. All reported cases of pulmonary embolism in congenital coagulation disorders have been gathered by a time-unlimited PubMed search. Cross-checking of the references listed at the end of the single papers was carried out to avoid omissions. Seventy-two patients had an objectively demonstrated pulmonary embolism. The event occurred in patients with fibrinogen, factor V, factor VIII (FVII), FVIII, FIX, and FXI deficiency, and in those with von Willebrands disease. No embolism was reported in FII, factor X, and FXIII deficiency. Thirty were women and 28 were men, whereas in the remaining 14 cases, sex was not reported. Age varied from 6 to 81 years (mean age 34.3 years). The management varied from only supportive to the administration of unfractionated heparin, low-molecular-weight heparin, and anti-vitamin K medications, accompanied by adequate replacement therapy. Evolution was fair or good in the majority of cases, but there were 10 fatalities. Risk factors were present in 61 patients. The most frequent of these were replacement therapy (35 cases), surgery (34), and old age (13). Some patients had more than one risk factor. Eleven patients had no risk factors. There are discrepancies in the prevalence of pulmonary embolism among different clotting disorders. The conditions most frequently affected are FVII deficiency and fibrinogen defects. The significance of the findings is discussed.

Myocardial Infarctions and Other Acute Coronary Syndromes in Rare Congenital Bleeding Disorders A Critical Analysis of All Reported Cases

Objective: To investigate the occurrence of myocardial infarction or other acute coronary syndromes in rare congenital bleeding disorders. Patients: All patients with factor I (FI), factor II (FII), factor V (FV), factor VII (FVII), factor X (FX), factor XI (FXI), or factor XIII (FXIII) deficiency or abnormality reported to have presented a myocardial infarction or another acute coronary syndrome were investigated. The condition had to be demonstrated by objective means, including a coronary/angiography. Cases of stable angina were excluded. Results: A total of 53 patients (4 had FI, 2 had FV, 2 had FVII, 36 had FXI, 1 had FXIII deficiency, and 8 patients had platelet disorders) met the inclusion criteria . No patient with FII or FX deficiency and acute coronary disease met the inclusion criteria. In the majority of patients, common risk factors were present, namely hypertension, hypercholesterolemia, smoking, and diabetes. Replacement therapy was involved in 5 cases. Conclusion: The congenital hypocoagulability present in these patients was unable to allow a protection from acute coronary diseases. The significance of the findings is discussed.

Congenital factor XI and factor VII deficiencies assure an apparent opposite protection against arterial or venous thrombosis: An intriguing observation†

Objective: To investigate the prevalence and type of thrombotic events reported in patients with congenital factor XI (FXI) or factor VII (FVII) deficiency. Patients and methods: Data on all patients with congenital FXI or FVII deficiency and a thrombotic event were gathered by means of a time unlimited PubMed search carried out in June 2014 and in February 2015. Appropriate keywords including the medical subject headings were used in both instances. Side tables were also consulted and cross-checking of the references was carried out to avoid omissions. The thrombosis event had to be proven by objective methods. Results: Forty-three patients with FXI deficiency had arterial thrombosis and only eight had venous thrombosis. On the contrary, only five patients with FVII deficiency had arterial thrombosis whereas 31 patients had venous thrombosis. The arterial/venous ratios were 5.37 and 0.17 for FXI or FVII, respectively. Conclusions: Arterial thrombosis is frequent in FXI deficiency whereas venous thrombosis is rare. The reverse is true for FVII deficiency. The significance of these findings is discussed especially in view of the recent use of synthetic anti-FXI compounds in the prophylaxis of post-orthopedic surgery of venous thrombosis complications.

Effect of busulfan on JAK2V617F allele burden.

We read with interest the paper from Kuriakose et al .[1][1] regarding the dramatic decrease of JAK2 V617F allele burden (AB) observed in 5 patients with polycythemia vera (PV) treated with busulfan (BU). Interestingly, a patient with 100% AB obtained the disappearance of the mutation within three

Two novel missense mutations in EPOR gene causes erythrocytosis in two unrelated patients

Bradford, P.T., Devesa, S.S., Anderson, W.F. & Toro, J.R. (2009) Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood, 113, 5064–5073. Burt, R.K., Guitart, J., Traynor, A., Link, C., Rosen, S., Pandolfino, T. & Kuzel, T.M. (2000) Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect. Bone Marrow Transplantation, 25, 111–113. Canninga-van Dijk, M.R., Sanders, C.J., Verdonck, L.F., Fijnheer, R. & van den Tweel, J.G. (2003) Differential diagnosis of skin lesions after allogeneic haematopoietic stem cell transplantation. Histopathology, 42, 313–330. Favre, A., Cerri, A., Bacigalupo, A., Lanino, E., Berti, E. & Grossi, C.E. (1997) Immunohistochemical study of skin lesions in acute and chronic graft versus host disease following bone marrow transplantation. The American Journal of Surgical Pathology, 21, 23–34. Heldal, D., Brinch, L., Evensen, S.A., Tjonnfjord, G.E., Aamodt, G., Elgjo, K. & Sviland, L. (2004) Skin biopsies for early diagnosis and prognosis of graft-versus-host disease in recipients of allogeneic stem cells from blood or bone marrow. Bone Marrow Transplantation, 34, 345–350. Hilgendorf, I., Greinix, H., Halter, J.P., Lawitschka, A., Bertz, H. & Wolff, D. (2015) Long-term follow-up after allogeneic stem cell transplantation. Deutsches € Arzteblatt International, 112, 51–58. Hosing, C., Bassett, R., Dabaja, B., Talpur, R., Alousi, A., Ciurea, S., Popat, U., Qazilbash, M., Shpall, E.J., Oki, Y., Nieto, Y., Pinnix, C., Fanale, M., Maadani, F., Donato, M., Champlin, R. & Duvic, M. (2015) Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, 26, 2490–2495. Lechowicz, M.J., Lazarus, H.M., Carreras, J., Laport, G.G., Cutler, C.S., Wiernik, P.H., Hale, G.A., Maharaj, D., Gale, R.P., Rowlings, P.A., Freytes, C.O., Miller, A.M., Vose, J.M., Maziarz, R.T., Montoto, S., Maloney, D.G. & Hari, P.N. (2014) Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplantation, 49, 1360– 1365. Sloane, J.P., Elliott, C.J. & Powles, R. (1988) HLADR expression in epidermal keratinocytes after allogeneic bone marrow transplantation. Relationship to histology, rash, marrow purging, and systemic graft-versus-host disease. Transplantation, 46, 840–844. Wingard, J.R., Majhail, N.S., Brazauskas, R., Wang, Z., Sobocinski, K.A., Jacobsohn, D., Sorror, M.L., Horowitz, M.M., Bolwell, B., Rizzo, J.D. & Soci e, G. (2011) Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29, 2230–2239.